Genmab — Maj 2023
-
Antibody Architects https://www.youtube.com/watch?v=Yh9SInylMvk
-
Genmab vil blive presset hvis CART virkelig vil få et større patientgrundlag end det ser ud til lige nu. JNJ ligner nogen der tror lidt på det https://finance.yahoo.com/news/johnson-johnson-ignites-car-t-181429711.html
-
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
05/03/23 -- TEPEZZA
(teprotumumab-trbw) Net Sales of $405.3 Million -- https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-first-quarter-2023-financial -
Jo, men: More recently, the Company has seen the expansion drive positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. As new prescribers and patients work through the reimbursement process, the Company expects a more meaningful impact to net sales later in the year.
-
Japan Grants Sakigake Designation to Satralizumab, Lu AF82422 | PHARMA JAPAN
The Ministry of Health, Labor and Welfare (MHLW) on March 24 granted sakigake designation to two API…
PHARMA JAPAN (pj.jiho.jp)
-
Det går da meget godt i dag....minus Genmab.
-
new trial by the University of Birmingham (Genmab collaborates) in Relapsed Follicular Lymphoma, containing Epcoritamab + lenalidomide. Interesting how 2 of the experimental arms will open only in 2025 and 2027 with drugs still to be announced. https://clinicaltrials.gov/ct2/show/NCT05848765
-
Biontech conf call https://www.fool.com/earnings/call-transcripts/2023/05/08/biontech-se-bntx-q1-2023-earnings-call-transcript/ "in principle, FixVac could be an option for patients with advanced metastatic disease. But again, here, it's a question of the combination compounds. And this is something that is now in the focus of our upcoming studies evaluating the use of these vaccines in combination with our checkpoint immunomodulators, for example, the bispecific BNT312 and BNT311 molecules,
" -
https://labuonasalute.it/2023/05/08/tumori-del-sangue-3.html teclistamab in Italie now
-
Ofte ser man biotech aktier stige frem mod mulig godkendelse. Genmab går i den anden retning. Nogen der ved om der er analytikere der hælder til et nej i denne omgang?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind